Clovis Oncology Probability of Future Stock Price Finishing Over 65.29

CLVSDelisted Stock  USD 0.09  0.02  24.00%   
Clovis Oncology's future price is the expected price of Clovis Oncology instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Clovis Oncology performance during a given time horizon utilizing its historical volatility. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
  
Please specify Clovis Oncology's target price for which you would like Clovis Oncology odds to be computed.

Clovis Oncology Target Price Odds to finish over 65.29

The tendency of Clovis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 65.29  or more in 90 days
 0.09 90 days 65.29 
close to zero percent
Based on a normal probability distribution, the odds of Clovis Oncology to move over $ 65.29  or more in 90 days from now is close to zero percent (This Clovis Oncology probability density function shows the probability of Clovis Stock to fall within a particular range of prices over 90 days) . Probability of Clovis Oncology price to stay between its current price of $ 0.09  and $ 65.29  at the end of the 90-day period is about 71.71 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.75 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Clovis Oncology will likely underperform. Additionally Clovis Oncology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
   Clovis Oncology Price Density   
       Price  

Predictive Modules for Clovis Oncology

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Clovis Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Clovis Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.090.090.10
Details
Intrinsic
Valuation
LowRealHigh
0.090.090.10
Details
Naive
Forecast
LowNextHigh
0.130.130.13
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.090.090.09
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Clovis Oncology. Your research has to be compared to or analyzed against Clovis Oncology's peers to derive any actionable benefits. When done correctly, Clovis Oncology's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Clovis Oncology.

Clovis Oncology Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Clovis Oncology is not an exception. The market had few large corrections towards the Clovis Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Clovis Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Clovis Oncology within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-1.28
β
Beta against NYSE Composite2.75
σ
Overall volatility
0.1
Ir
Information ratio -0.08

Clovis Oncology Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Clovis Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Clovis Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Clovis Oncology is not yet fully synchronised with the market data
Clovis Oncology has some characteristics of a very speculative penny stock
Clovis Oncology has a very high chance of going through financial distress in the upcoming years
Clovis Oncology has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 148.76 M. Net Loss for the year was (264.52 M) with profit before overhead, payroll, taxes, and interest of 115.3 M.
Clovis Oncology currently holds about 94.58 M in cash with (196.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Clovis Oncology Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Clovis Stock often depends not only on the future outlook of the current and potential Clovis Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Clovis Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding121.2 M
Cash And Short Term Investments143.4 M

Clovis Oncology Technical Analysis

Clovis Oncology's future price can be derived by breaking down and analyzing its technical indicators over time. Clovis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Clovis Oncology. In general, you should focus on analyzing Clovis Stock price patterns and their correlations with different microeconomic environments and drivers.

Clovis Oncology Predictive Forecast Models

Clovis Oncology's time-series forecasting models is one of many Clovis Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Clovis Oncology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Clovis Oncology

Checking the ongoing alerts about Clovis Oncology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Clovis Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Clovis Oncology is not yet fully synchronised with the market data
Clovis Oncology has some characteristics of a very speculative penny stock
Clovis Oncology has a very high chance of going through financial distress in the upcoming years
Clovis Oncology has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 148.76 M. Net Loss for the year was (264.52 M) with profit before overhead, payroll, taxes, and interest of 115.3 M.
Clovis Oncology currently holds about 94.58 M in cash with (196.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing in Clovis Stock

If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world